Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Payoneer Q1 2026 Earnings Call - B2B Volume More Than Doubles as Core Profitability Hits Record
Payoneer delivered a strong first quarter with accelerating revenue growth ex-interest of 11% year-over-year, driven by a 44% surge in B2B volume that more than doubled from the previous quarter. The ...
- Revenue ex-interest accelerated 11% year-over-year, with B2B volume surging 44%, more than doubling from Q4’s 21% growth rate.
- Core adjusted EBITDA ex-interest hit a record $18 million, reflecting substantial operating leverage and margin expansion.
- Full-year 2026 guidance raised: total revenue expected between $1.1B and $1.14B, with mid-point up $10M from prior guidance.
- +7 more takeaways
Bentley Systems Q1 2026 Earnings Call - AI-Driven API Consumption and Asset Analytics Accelerate Growth
Bentley Systems delivered a strong Q1 2026 with 14.5% year-over-year revenue growth to $424 million and 11.5% constant currency ARR growth to $1.495 billion. The company is pivoting from traditional s...
- Q1 2026 revenue grew 14.5% year-over-year to $424 million, with subscription revenues representing 93% of the total and growing 14.7%.
- Constant currency ARR reached $1.495 billion, marking an 11.5% year-over-year increase and a 2.5% sequential growth rate.
- Bentley Asset Analytics, a new AI-driven business unit, has already surpassed a $50 million annual revenue run rate, signaling strong demand for digital twin optimization.
- +7 more takeaways
Ligand Pharmaceuticals Q1 2026 Earnings Call - XOMA Royalty Acquisition and FILSPARI Expansion Drive 56% Royalty Growth
Ligand Pharmaceuticals delivered a strong first quarter of 2026, with royalty revenue surging 56% year-over-year to $43 million and adjusted EPS climbing 23% to $1.63. The results underscore the succe...
- Royalty revenue surged 56% year-over-year to $43 million in Q1 2026, while total revenue grew 14% to $52 million, reflecting broad-based strength across the portfolio rather than reliance on a single asset.
- Adjusted EPS rose 23% to $1.63, validating the operating leverage of Ligand’s 2022 pivot to a lean, pure royalty aggregation model that has cut headcount from nearly 200 to roughly 40 and reduced operating expenses from $90 million to $40 million.
- The acquisition of XOMA Royalty is the defining catalyst for 2026. The deal adds over 120 assets, including seven commercial products and nearly double the late-stage clinical pipeline, and is expected to close in Q3 2026.
- +7 more takeaways
Mativ Q1 2026 Earnings Call - Margin Expansion and Cash Flow Beat Amidst Input Cost Inflation
Mativ delivered its strongest first-quarter consolidated margin and cash flow performance since its mid-2022 merger, driven by aggressive cost-cutting, strategic pricing actions, and operational disci...
- Adjusted EBITDA rose 28% year-over-year to $47.5 million, marking the company's strongest Q1 margin performance since the mid-2022 merger.
- Adjusted EBITDA margin expanded 220 basis points to 9.9%, driven by favorable price-to-input cost ratios and lower manufacturing expenses.
- Free cash flow improved by over $22 million year-over-year to a use of $7 million, representing the best Q1 cash flow performance since the merger.
- +7 more takeaways
LifeStance Health Q1 2026 Earnings Call - Raised Full-Year Guidance on 21% Revenue Growth and 48% EBITDA Surge
LifeStance Health delivered a robust first quarter, with revenue jumping 21% to $403 million and adjusted EBITDA surging 48% to $51 million. Management exceeded expectations across the board, driven b...
- Revenue surged 21% to $403 million, beating expectations on higher visit volumes (up 18%) and favorable payer rates (total revenue per visit up 3%).
- Adjusted EBITDA jumped 48% to $51 million, reflecting a 12.7% margin and outpacing guidance due to center margin expansion and lower spending.
- Full-year revenue guidance raised by $25 million at the midpoint to $1.64-$1.68 billion, with adjusted EBITDA guidance lifted by $15 million to $200-$220 million.
- +7 more takeaways
NETSCOUT Q4 FY2026 Earnings Call - Cybersecurity Outpaces Service Assurance as AI-Ready Data Strategy Takes Center Stage
NETSCOUT delivered a solid fiscal year 2026, with revenue up 4.5% to $860 million and diluted EPS growing nearly 12% to $2.48, beating the high end of guidance. The quarter was marked by a slight reve...
- Full-year revenue grew 4.5% to $859.5 million, driven by double-digit growth in cybersecurity (up 7.8%) and steady service assurance (up 2.6%).
- Diluted EPS rose nearly 12% to $2.48, exceeding the high end of guidance, supported by margin expansion and disciplined cost management.
- Gross margin improved 0.8 percentage points to 80.8%, while operating margin expanded 1.7 points to 25.4%, reflecting favorable product mix and volume.
- +12 more takeaways
Shake Shack Q1 2026 Earnings Call - Accelerating Development and Margin Expansion Despite Weather Headwinds
Shake Shack delivered a resilient first quarter, growing total revenue by 14.3% and same-shack sales by 4.6%, marking its 21st consecutive quarter of positive comp growth. The company navigated signif...
- Total revenue grew 14.3% year-over-year to $366.7 million, driven by 14.1% system-wide sales growth and strong international licensing performance.
- Same-shack sales increased 4.6%, fueled by 1.4% traffic growth and 3.2% price mix, marking the third consecutive quarter of positive traffic.
- Restaurant-level profit margin expanded 50 basis points to 21.2%, offsetting high beef inflation through labor efficiency and supply chain optimizations.
- +12 more takeaways
The Carlyle Group Q1 2026 Earnings Call - Record Realizations and $5B Fund Innovation Drive Fee Growth
The Carlyle Group delivered a resilient Q1 2026, anchored by record U.S. buyout realizations exceeding $12 billion and a landmark $5 billion capital-efficient investment solution for its next fund. Fe...
- Record U.S. buyout realizations exceeded $12 billion, marking the third-best quarter ever and returning capital to investors faster than the industry average.
- A groundbreaking $5 billion investment solution was secured for the next U.S. buyout fund, combining fund access with tailored liquidity for cornerstone investors.
- Fee-related earnings (FRE) reached $300 million with a 47% margin, up from $290 million in Q4, driven by growth in AlpInvest and global credit.
- +7 more takeaways
Genco Shipping & Trading Limited Q1 2026 Earnings Call - Dividend Surges to $2.50 as Structural Dry Bulk Tightness Drives Record TCE
Genco Shipping & Trading Limited reported a strong first quarter 2026, driven by a 63% year-over-year increase in time charter equivalent rates to $19,346 per day and a 358% jump in adjusted EBITDA. T...
- Q1 2026 TCE rates surged 63% year-over-year to $19,346 per day, the highest first-quarter average since 2022, driving a 358% increase in adjusted EBITDA to $36.2 million.
- Management projects a full-year 2026 dividend of approximately $2.50 per share, with Q2 expected at $0.70 per share, reflecting a transparent formula tied to operating cash flow.
- Genco maintains an industry-low net loan-to-value ratio of 20% and a cash flow breakeven rate under $10,000 per day, providing significant operating leverage in a strengthening market.
- +7 more takeaways
EDAP TMS Q1 2026 Earnings Call - Record HIFU Revenue and Multi-Indication Expansion
EDAP TMS reported a record first quarter for 2026, driven by a 78% year-over-year surge in HIFU revenue to $11.6 million, fueled by 11 Focal One capital sales and a 53% jump in U.S. procedure volumes....
- Record Q1 2026 total revenue of $17.8 million, up 25% year-over-year, driven by a 78% surge in HIFU revenue to $11.6 million.
- Focal One robotic HIFU capital sales hit 11 units in Q1, with 10 net placements, reinforcing strong demand across U.S. and international markets.
- U.S. procedure volumes jumped 53% year-over-year, reflecting growing physician adoption and expanded training programs at key academic and community centers.
- +10 more takeaways